(NASDAQ: IMMX) IMMIX Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.2%.
IMMIX Biopharma's earnings in 2025 is -$20,896,913.On average, 1 Wall Street analyst forecast IMMX's earnings for 2025 to be -$20,350,424, with the lowest IMMX earnings forecast at -$20,350,424, and the highest IMMX earnings forecast at -$20,350,424.
In 2026, IMMX is forecast to generate -$19,235,332 in earnings, with the lowest earnings forecast at -$19,235,332 and the highest earnings forecast at -$19,235,332.